April 06, 2015; 84 (14 Supplement) April 23, 2015
Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263)
Alasdair Coles, Douglas Arnold, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D Alastair S Compston
First published April 8, 2015,
Alasdair Coles
10University of Cambridge School of Clinical Medicine Cambridge United Kingdom
Douglas Arnold
8NeuroRx Research Montreal QC Canada
7Montréal Neurological Institute, McGill University Montreal QC Canada
Jeffrey Cohen
2Cleveland Clinic Cleveland OH United States
Edward Fox
1Central Texas Neurology Consultants Round Rock TX United States
Hans-Peter Hartung
5Heinrich-Heine University Düsseldorf Germany
Eva Havrdova
3First Medical Faculty, Charles University in Prague Prague Czech Republic
Krzysztof Selmaj
6Medical University of Lodz Lodz Poland
David Margolin
4Genzyme, a Sanofi company Cambridge MA United States
Linda Kasten
9PROMETRIKA, LLC Cambridge MA United States
Michael Panzara
4Genzyme, a Sanofi company Cambridge MA United States
D Alastair S Compston
10University of Cambridge School of Clinical Medicine Cambridge United Kingdom
Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-Remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years (P7.263)
Alasdair Coles, Douglas Arnold, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D Alastair S Compston
Neurology Apr 2015, 84 (14 Supplement) P7.263;
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 84 no. 14 Supplement P7.263
Print ISSN:
Online ISSN:
History:
- First Published April 8, 2015.
Copyright & Usage:
Copyright © 2015 by AAN Enterprises, Inc.
Author Disclosures
- Alasdair Coles10,
- Douglas Arnold8,7,
- Jeffrey Cohen2,
- Edward Fox1,
- Hans-Peter Hartung5,
- Eva Havrdova3,
- Krzysztof Selmaj6,
- David Margolin4,
- Linda Kasten9,
- Michael Panzara4 and
- D Alastair S Compston10
- Alasdair Coles10,
- Douglas Arnold8,7,
- Jeffrey Cohen2,
- Edward Fox1,
- Hans-Peter Hartung5,
- Eva Havrdova3,
- Krzysztof Selmaj6,
- David Margolin4,
- Linda Kasten9,
- Michael Panzara4 and
- D Alastair S Compston10
- 1Central Texas Neurology Consultants Round Rock TX United States
- 2Cleveland Clinic Cleveland OH United States
- 3First Medical Faculty, Charles University in Prague Prague Czech Republic
- 4Genzyme, a Sanofi company Cambridge MA United States
- 5Heinrich-Heine University Düsseldorf Germany
- 6Medical University of Lodz Lodz Poland
- 7Montréal Neurological Institute, McGill University Montreal QC Canada
- 8NeuroRx Research Montreal QC Canada
- 9PROMETRIKA, LLC Cambridge MA United States
- 10University of Cambridge School of Clinical Medicine Cambridge United Kingdom
Article usage
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.